Every trading day, be ready to attack the market instead of reacting to the
market.

You will know where the key technical resistance and support levels are and what
the market is likely to do next. iStock will arm you with a target list of stocks
to buy and sell - right now - based on our exclusive, proprietary trading models.
You will also receive monthly ETF model portfolio and trend trader model portfolio

For the three months ended September 30, 2012 the Company reported a
loss of $811,164, or $0.01 per common share, compared with a loss of
$591,022 or $0.01 per common share for the three months ended September
30, 2011. At September 30, 2012, Pivotal's current assets totaled
$1,274,508 compared with $2,215,820 at December 31, 2011. The decrease
in current assets during the nine months ended September 30, 2012, is
primarily due to a reduction in cash utilized in the expansion of sales
and marketing of our lead product VASCAZEN®.

"Subsequent to the end of the third quarter Pivotal received additional
funding from its private placement and Crossover Healthcare Fund
remains committed to and will continue to fund the company in tranches
at the original terms of the agreement until the round of financing is
complete," stated Eugene Bortoluzzi, Chief Executive Officer and Chief
Financial Officer."

Highlights for 2012:

April 3, 2012 - the Company began trading in the U.S. on the OTC
Markets' QX Marketplace, under the symbol PVTTF;

April 30, 2012 - the Company announced its 2011 financial results;

May 22, 2012 - the Company announced first prescription sales in the
U.S.;

May 28, 2012 - the Company announced its Q1 financial results;

June 25, 2012 - the Company announced U.S. Institutional Private
Placement for $5M CDN;

August 9, 2012 - the Company announced that data from a scientific
study, presented at the 17th World Congress On Heart Disease demonstrated the superiority of VASCAZEN®'s unique formulation;

August 23, 2012 - the Company announced that further data presented at
the European Society of Cardiology Congress, demonstrated the
superiority of VASCAZEN®'s unique formulation;

August 28, 2012 - the Company announced its Q3 financial results;

August 23, 2012-the Company announced it generated positive feedback at
the European Society of Cardiology Congress

September 6, 2012-the Company announced a presentation at the Rodman &
Renshaw 14th Annual Healthcare Conference

October 9, 2012-the Company announced it exhibited at the 2012
Cardiometabolic Health Congress

October 29, 2012-the Company announced it filed amended 2012 Q1 and Q2
financial statements to more fully comply with IFRS disclosure
requirements.

November 5, 2012- the Company announced it exhibited at the American
Heart Associations (AHA) Scientific Sessions.

The unaudited consolidated financial statements, accompanying notes and
Management's Discussion and Analysis for the three and nine months
ended September 30, 2012, are accessible on Pivotal's website at www.pivotaltherapeutics.us and on SEDAR (www.sedar.com).

About Pivotal Therapeutics Inc.
With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF); (CNSX: PVO) specialty
pharmaceutical company with a focus on cardiovascular disease and
overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications.

VASCAZEN® is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected
by a series of both issued and pending US and foreign patents and
commercialized as a prescription only Medical Food. This unique
formulation will provide the cornerstone upon which a family of cutting
edge combination products, with efficacy across a broad spectrum of
cardiac care, will be commercialized.

OMAZENTM is a >90% pure, proprietary EPA:DHA fatty acid formulation
commercialized for sale and distribution in Canada for the maintenance
of good health through elevating Omega-3 fatty acid levels. The unique
formulation and dosage will be available to patients and consumers who
realize the health benefits of Omega-3 supplementation with a quality
product.

Disclosure NoticeThe information contained in this document is as of November 29, 2012.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual results
to differ materially from those projected in such forward-looking
statements. These statements can be identified by the use of words such
as "will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause actual
results to differ materially from those in forward looking statements
include the following: Pivotal's inability to obtain additional
financing on acceptable terms; growth in costs and expenses; inability
to compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance; risks
relating to the Company's ability to maintain its CSNX listing.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation
to publicly update or revise any forward-looking statements contained
in this document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.

Fundamental data is provided by Zacks
Investment Research, and Commentary, news and Press Releases provided by
YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not
intended for trading purposes or advice. iStockAnalyst.com is not an investment
adviser and does not provide, endorse or review any information or data contained
herein.
The blog articles are opinions by respective blogger. By using this site you are
agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither
iStockAnalyst nor any of its independent providers is liable for any informational
errors, incompleteness, or delays, or for any actions taken in reliance on information
contained herein. You are solely responsible for the investment decisions made by
you and the consequences resulting therefrom. By accessing the iStockAnalyst.com
site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based
on EOD data.